ArticleFrontiers in immunology2022
Designing a Novel Functional Peptide With Dual Antimicrobial and Anti-inflammatory Activities
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.Probiotics and antimicrobial proteins · 2026Article
- Integrating Computational and Experimental Approaches for the Discovery of Multifunctional Peptides from the Marine GastropodMarine drugs · 2026Article
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- Generation, Characterisation and Identification of Bioactive Peptides from Mesopelagic Fish Protein Hydrolysates Using In Silico and In Vitro Approaches.Marine drugs · 2024Article
- Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions.International journal of nanomedicine · 2024Review
- Short Antimicrobial Peptide Derived from the Venom Gland Transcriptome ofAntibiotics (Basel, Switzerland) · 2023Article
- The Identification of a Novel Spider Toxin Peptide, Lycotoxin-Pa2a, with Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2023Article
- The Contribution of Antimicrobial Peptides to Immune Cell Function: A Review of Recent Advances.Pharmaceutics · 2023Review
- Recombinant Antimicrobial Peptide OaBac5mini Alleviates Inflammation in Pullorum Disease Chicks by Modulating TLR4/MyD88/NF-κB Pathway.Animals : an open access journal from MDPI · 2023Article
- De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity.International journal of molecular sciences · 2022Article
- Designed Multifunctional Peptides for Intracellular Targets.Antibiotics (Basel, Switzerland) · 2022Review
- Identifying novel antimicrobial peptides from venom gland of spiderFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As spider venom is composed of various bioactive substances, it can be utilized as a platform for discovering future therapeutics. Host defense peptides are great candidates for developing novel antimicrobial agents due to their multifunctional properties. In this study, novel functional peptides were rationally designed to have dual antibacterial and anti-inflammatory activities with high cytocompatibility. Based on a template sequence from the transcriptome of spider
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.